Skip to main content
. Author manuscript; available in PMC: 2013 Aug 19.
Published in final edited form as: J Neuroimmune Pharmacol. 2011 Dec 10;7(2):388–400. doi: 10.1007/s11481-011-9325-0

Figure 5.

Figure 5

LM11A-31 efficacy varies with FIV load. FIV titers of 104, 105 and 106 TCID50/ml produced similar decreases in MAP-2 staining intensity. Addition of 10 nM LM11A-31 resulted in a significant recovery of MAP-2 in each case but the extent of recovery decreased from 172% (n=6) to 123% (n=7) and 56% (n=10) as the amount of FIV increased. Values are normalized to controls (100%).